Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immuneering Corporation - Class A Common Stock
(NQ:
IMRX
)
6.880
+0.930 (+15.63%)
Streaming Delayed Price
Updated: 2:40 PM EDT, Sep 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Immuneering Corporation - Class A Common Stock
< Previous
1
2
3
4
Next >
Immuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On Dips
August 25, 2025
Via
Stocktwits
Top stock movements in today's session.
August 21, 2025
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
August 21, 2025
Via
Benzinga
Top movers analysis in the middle of the day on 2025-08-21: top gainers and losers in today's session.
August 21, 2025
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via
Chartmill
Why Is Immuneering Stock Trading Higher On Tuesday?
January 07, 2025
Immuneering reveals promising Phase 2a pancreatic cancer trial updates for IMM-1-104, showcasing efficacy, safety, and future expansion plans.
Via
Benzinga
Why is Immuneering (IMRX) Stock Up 24% Today?
August 01, 2024
Up nearly 25% in today's session on a fast track designation for a key pancreatic cancer drug candidate, IMRX stock is coming into focus.
Via
InvestorPlace
There are notable gap-ups and gap-downs in today's session.
August 21, 2025
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
August 21, 2025
Via
Benzinga
Immuneering Posts Narrower Loss in Q2
August 13, 2025
Via
The Motley Fool
Topics
Intellectual Property
Curious about the stocks that are showing activity after the closing bell on Wednesday?
August 13, 2025
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via
Chartmill
Unusual volume stocks are being observed in Wednesday's session.
June 25, 2025
The trading volume of these stocks is deviating from the norm in today's session.
Via
Chartmill
These stocks have an unusual volume in today's session
June 20, 2025
Let's have a look at the stocks with an unusual volume in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 18, 2025
Via
Benzinga
Top movers in Wednesday's after hours session
June 18, 2025
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
Which stocks are experiencing notable movement on Wednesday?
June 18, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
June 18, 2025
Via
Benzinga
Here are the top movers in Wednesday's session.
June 18, 2025
Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally
June 17, 2025
The company plans to launch a pivotal trial in 2026 and expects additional clinical data and regulatory feedback by the end of 2025.
Via
Stocktwits
These stocks are moving in today's session
June 17, 2025
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
June 16, 2025
Via
Benzinga
These stocks are gapping in today's session
June 16, 2025
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
Maximize Your Trades: Pre-Market Insights And Key Stock Breakdowns
January 13, 2025
Via
Talk Markets
Topics
ETFs
Stocks / Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 07, 2025
Via
Benzinga
Mastering Market Chaos: StoryTrading’s Top 5 Stocks You Can’t Ignore
December 20, 2024
The trading landscape is alive with opportunity, shaped by a mix of macroeconomic events and sector-specific moves.
Via
Talk Markets
Topics
Stocks / Equities
Top Trade Picks Of The Day: Don’t Miss These Market Movers
December 17, 2024
Discover today’s top stock opportunities with our 4-pillar strategy, combining catalysts, sentiment, fundamentals, and technicals to highlight 6 must-watch trades before the market opens.
Via
Talk Markets
Topics
Stocks / Equities
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
December 13, 2024
Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks.
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
October 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 15, 2024
Via
Benzinga
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
October 02, 2024
A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar.
Via
Benzinga
Why Is Nanocap Immuneering Stock Trading Higher On Friday?
September 13, 2024
Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response rate...
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.